Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Stock Quote Today & Recent News Bristol-Myers Squibb Co BMY

Healthcare Biotechnology
Bristol-Myers Squibb Company is a global biopharmaceutical company. It is engaged in the discovery, development and delivery of transformational medicines for patients facing serious diseases in areas: oncology, hematology, immunology, cardiovascular, neuroscience and other areas. Its platforms comprise chemically synthesized or small molecule drugs, including protein degraders; drugs produced... see more
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >

Current News (NYSE:BMY)

Bristol Myers Squibb Receives Approval from the European Commission to Expand Use of CAR T Cell Therapy Breyanzi for Relapsed or Refractory Follicular Lymphoma

Business Wire 3 days ago

Bristol Myers Squibb to Report Results for First Quarter 2025 on April 24, 2025

Business Wire 4 days ago

ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of 2seventy bio, Inc.

PR Newswire 5 days ago

Bristol Myers Squibb Presents Late-Breaking Data from Phase 3 POETYK PsA-2 Trial Demonstrating Superiority of Sotyktu (deucravacitinib) Compared with Placebo in Adults with Psoriatic Arthritis

Business Wire 9 days ago

Bristol Myers Squibb Receives European Commission Approval for Opdivo® (nivolumab) plus Yervoy® (ipilimumab) for the First-Line Treatment of Adult Patients with Unresectable or Advanced Hepatocellular Carcinoma

Business Wire 10 days ago

Bristol Myers Squibb Announces Dividend

Business Wire 13 days ago

Bristol Myers Squibb to Participate in Upcoming Investor Conferences

Business Wire February 25, 2025

U.S. Food and Drug Administration Accepts Bristol Myers Squibb's Supplemental Biologics License Application for Opdivo® Plus Yervoy® for Patients with Unresectable or Metastatic Microsatellite Instability-High or Mismatch Repair Deficient...

Business Wire February 24, 2025

Bristol Myers Squibb Announces Opdivo® Plus Chemotherapy as the First and Only Neoadjuvant-Only Immuno-Oncology Therapy to Demonstrate Statistically Significant and Clinically Meaningful Overall Survival in Resectable Non-Small Cell Lung Cancer

Business Wire February 19, 2025
View More News ››

Opinion & Analysis (NYSE:BMY)

Big pharma sets its sights on NASH epidemic

The Life Sciences Report May 18, 2017

Use stock volatility to invest in innovative oncology companies: JMP Security's Michael King Jr.

Gail Dutton October 15, 2015

Opportunities in cancer immunotherapy throttle up: George Zavoico of JonesTrading

George S. Mack June 25, 2015

U.S. Tech, Dollar & Health Care ETFs To Watch This Week

Benzinga.com  April 26, 2015

Drug ETFs Attractive Buys On Pullback

Benzinga.com  October 22, 2014

Pharma ETFs in Focus on String of Earnings Beat - ETF News And Commentary

Benzinga.com  July 30, 2014
View More Opinion ››

Bullboard Posts (NYSE:BMY)

Bristol Myers Squibb Showcases the Continued Strength of its

NEWS: $BMY Bristol Myers Squibb Showcases the Continued Strength of its Cardiovascular Portfolio with New Clinical and Real-World Data...
whytestocks - November 11, 2024

Johnson & Johnson Beats Wall Street Estimates. Is It Time to

NEWS: $BMY Johnson & Johnson Beats Wall Street Estimates. Is It Time to Buy, Sell, or Hold?2024-10-16 05:27:00 ET The healthcare...
whytestocks - October 16, 2024

3 High-Yield Dividend Stocks With Payout Ratios Below 75%

Breaking News: $BMY 3 High-Yield Dividend Stocks With Payout Ratios Below 75%2024-08-28 07:00:00 ET High-yield dividend stocks can be...
whytestocks - August 28, 2024

RE:RE:RE:RE:IVERMICTIN KILLS COVID 19 !

Microscopy Expert: Vials Contain Graphene Oxide, Parasites ... https://forbiddenknowledgetv.net/microscopy-expert...
zeropointenergy - October 16, 2021

RE:RE:RE:IVERMICTIN KILLS COVID 19 !

THE FAUCI INDICTMENT (Video) — SOTN: Alternative News ...   Oct 09, 2021 · THE FAUCI INDICTMENT…...
zeropointenergy - October 16, 2021

RE:RE:RE:IVERMICTIN KILLS COVID 19 !

IS THIS WHY PEOPLE ARE SICK OPP NEEDS TO INVESTIGATE!  Graphene in our foods, not just shots - ugetube.com https://ugetube...
zeropointenergy - October 10, 2021
View more Bullboard ››

Cizzle Brands Corp.

Cizzle Brands Corp.

Cizzle Brands Corporation is a Canada-based consumer-packaged goods company. The Company's activities consist of developing ...
View More »